ValiRx PLC Result of AGM (2737E)
28 Giugno 2023 - 3:15PM
UK Regulatory
TIDMVAL
RNS Number : 2737E
ValiRx PLC
28 June 2023
28 June 2023
ValiRx PLC ("ValiRx" or the "Company")
Result of AGM
London, UK - ValiRx Plc (AIM: VAL), a life science company
focusing on early-stage cancer therapeutics and women's health
announces that at its Annual General Meeting ("AGM") held earlier
today, all resolutions except special resolutions 12
(disapplication of statutory pre-emption rights (allowing issue of
shares for cash)) and 13 (disapplication of statutory pre-emption
rights (share options)) were passed.
Details of the votes received will be available shortly on the
Company's website.
The Directors of the Company take responsibility for this
announcement.
*** ENDS ***
For more information, please contact:
ValiRx plc Tel: +44 (0) 2476
796496
Dr Suzanne Dilly, CEO www.valirx.com
Suzanne.Dilly@valirx.com
V Formation (Public Relations) +44 (0) 115 787
0206
Lucy Wharton - Senior PR Executive www.vformation.biz
Sue Carr - Director
lucy@vformation.biz
sue@vformation.biz
--------------------------
Cairn Financial Advisers LLP (Nominated Tel: +44 (0) 20
Adviser) 7213 0880
Liam Murray/Jo Turner/Ludovico Lazzaretti
--------------------------
Cenkos Securities plc (Joint Broker) Tel: +44 (0) 20
7397 8900
Dale Bellis/Michael Johnson (Sales)
Callum Davidson/Giles Balleny (Corporate
Finance)
--------------------------
Turner Pope Investments (Joint Broker) Tel: +44 (0) 20
James Pope / Andy Thacker 3657 0050
--------------------------
Notes for Editors
About ValiRx
ValiRx is a life science company focused on early-stage cancer
therapeutics and women's health, accelerating the translation of
innovative science into impactful medicines to improve patient
lives.
ValiRx provides the scientific, financial, and commercial
framework for enabling rapid translation of innovative science into
clinical development.
Using its extensive and proven experience in research and drug
development, the team at ValiRx selects and incubates promising
novel drug candidates and guides them through an optimised process
of development, from pre-clinical studies to clinic and
investor-ready assets.
ValiRx connects diverse disciplines across scientific,
technical, and commercial domains, with the aim of achieving a more
streamlined, less costly, drug development process. The team works
closely with carefully selected collaborators and leverages the
combined expertise required for science to advance.
Lead candidates from ValiRx's portfolio are outlicensed or
partnered with investors through ValiRx subsidiary companies for
further clinical development and commercialisation.
ValiRx listed on the AIM Market of the London Stock Exchange in
October 2006 and trades under the ticker symbol: VAL.
For further information, visit: www.valirx.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RAGSEDFDAEDSEFM
(END) Dow Jones Newswires
June 28, 2023 09:15 ET (13:15 GMT)
Grafico Azioni Valirx (LSE:VAL)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Valirx (LSE:VAL)
Storico
Da Mag 2023 a Mag 2024
